After Lupin Launch, Cipla Introduces US Brovana Rival

Company Launches Generic Version Of Sunovion’s Arformoterol Brand

After Lupin’s launch of an authorized generic, Cipla has entered the US market with its own generic rival to Sunovion’s Brovana, after receiving the FDA approval for the inhalation solution. Axar Pharma and Glenmark also currently hold approvals and Teva a tentative approval for arformoterol tartrate abbreviated new drug applications.

Approved
FDA approves Cipla’s arformoterol tartrate inhalation solution • Source: Alamy

Cipla Limited has announced receiving final approval for its generic version of Sunovion’s Brovana (arformoterol tartrate) inhalation solution from the US Food and Drug Administration. The company launched the product immediately in a 15mcg/2ml presentation.

Early this month, Lupin launched an authorized generic rival to Brovana, available as arformoterol tartrate inhalation solution in 15mcg/2ml unit-dose vials, for use by nebulization only. Also see "Lupin Gets Head Start On Brovana With US Authorized Generic" - Generics Bulletin, 4 June, 2021

More from Products

More from Generics Bulletin